IMPACT Study for those newly diagnosed with T1D
Type1Screen is supporting the enrolment of young adults with a recent diagnosis of type 1 diabetes (T1D) to a new drug trial. This randomized, placebo-controlled, multi-centre clinical trial will evaluate the treatment of the Imotope™ IMCY-0098 and its effect on the preservation of beta-cell function in people with a recent onset T1D.
Aim
The study aims to investigate the effect of two doses of IMCY-0098 upon treatment-specific biomarkers and the effect of study medication on beta-cell function in adults with recently diagnosed type 1 diabetes.
Eligibility to take part
- Aged 18 to 44 years
- Diagnosed with type 1 diabetes (first insulin treatment) within 9 weeks of study screening visit.
How do I take part?
- Contact Type1Screen via
- email type1screen@mh.org.au
- phone (03) 9342 7063
